Isolated neuronal growth cones from developing rat forebrain possess adenylate cyclase activity which can be augmented by various receptor agonists.
Isolated neuronal growth cones from neonatal rat forebrain were found to contain a high specific activity of adenylate cyclase (61 pmol cyclic AMP/min/mg protein) compared to the pelleted starting homogenate (5 pmol cyclic AMP/min/mg protein). Forskolin at 10(-4) M increased adenylate cyclase activity in both the pelleted homogenate and growth cone fraction by 70 and 217 pmol cyclic AMP/min/mg protein, respectively, over basal levels. The incremental effect of forskolin was 3-fold greater in the growth cone fraction than in the pelleted homogenate. However, relative to basal levels in each of the two fractions, forskolin increased adenylate cyclase activity in the growth cone fraction by only approx. 5-fold compared to 15-fold in the pelleted homogenate. Dopamine (10(-4) M), vasoactive intestinal polypeptide (10(-6) M) and isoproterenol (10(-5) M) also augmented adenylate cyclase activity in the two fractions. In the growth cone fraction, dopamine and vasoactive intestinal polypeptide produced a stimulation over basal levels by approx. 20 pmol cyclic AMP/min/mg protein while isoproterenol produced a stimulation of approx. 10 pmol cAMP/min/mg protein. The incremental effects of these receptor agonists in the growth cone fraction are approx. 5-fold greater than in the pelleted homogenate. The dopamine-sensitive adenylate cyclase activity in the growth cone fraction could be blocked by the compound SCH23390, a selective D1 receptor antagonist. At saturating concentrations, all combinations of dopamine, vasoactive intestinal polypeptide and isoproterenol were found to be completely additive on adenylate cyclase activity in the growth cone fraction.(ABSTRACT TRUNCATED AT 250 WORDS)
Lockerbie
R O
RO
College de France, I.N.S.E.R.M. U. 114, Paris, France.
Hervé
D
D
Blanc
G
G
Tassin
J P
JP
Glowinski
J
J
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D000831:Animals, Newborn; D005576:Colforsin / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D005625:Frontal Lobe / Q000201:enzymology* / Q000502:physiology / Q000648:ultrastructure; D007545:Isoproterenol / Q000494:pharmacology; D051381:Rats; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000502:physiology*; D013347:Subcellular Fractions / Q000201:enzymology / Q000502:physiology; D013569:Synapses / Q000201:enzymology* / Q000502:physiology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
D017981:Receptors, Neurotransmitter; D005576:Colforsin; D014660:Vasoactive Intestinal Peptide; D000262:Adenylyl Cyclases; D007545:Isoproterenol; D004298:Dopamine